Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill shows promise in early trial for Hard-to-Treat cancers

NCT ID NCT06717750

First seen Feb 02, 2026 · Last updated May 24, 2026 · Updated 17 times

Summary

This early-phase study tests an experimental oral drug, CSCJC3456, in 102 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants take the pill by mouth, and researchers monitor side effects and any anti-cancer activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110001, China

    Contact

Conditions

Explore the condition pages connected to this study.